Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 69282 for:    cancer

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03596073
Recruitment Status : Recruiting
First Posted : July 23, 2018
Last Update Posted : November 14, 2018
Sponsor:
Information provided by (Responsible Party):
Shadmehr Demehri, Massachusetts General Hospital

Brief Summary:
This research study is studying a topical ointment called calcipotriene to see if it can stimulate the immune cells against the breast lesion in ways that would prevent its recurrence after surgical removal

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Topical Calcipotriene Ointment Other: Topical Vaseline Phase 1

Detailed Description:

The investigators are doing this research study to find out how topical calcipotriene ointment affect people who have breast cancer, and what impact that may have on those who are at risk of developing breast cancer in the future. The investigators hope that what they learn will lead to the development of a new medication for the treatment and prevention of breast cancer.

Abnormal breast lesions can be benign, premalignant or malignant. These lesions are being targeted by the topical calcipotriene ointment. The investigators aim to determine whether this topical treatment can stimulate the immune cells against the breast lesion in ways that would prevent its recurrence after surgical removal.

Calcipotriene ointment is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis, but calcipotriene ointment is not approved by the FDA to treat breast cancer.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
Actual Study Start Date : November 7, 2018
Estimated Primary Completion Date : July 31, 2021
Estimated Study Completion Date : July 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Topical Calcipotriene Ointment
-Topical Calcipotriene Ointment will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
Drug: Topical Calcipotriene Ointment
Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.

Placebo Comparator: Topical Vaseline
-Topical Vaseline will be administered by the participants to their upper extremities twice a day for the period between core biopsy and surgical removal of their breast lesion
Other: Topical Vaseline
Placebo




Primary Outcome Measures :
  1. The changes in the magnitude of CD3+ T cell infiltration in tumor microenvironment [ Time Frame: 3 Weeks ]
    The change in the number of CD3+ T cells per high power microscope field in tumor microenvironment from the time of initial needle core biopsy to surgical excision.


Secondary Outcome Measures :
  1. The comprehensive changes in tumor immune microenvironment [ Time Frame: 3 Weeks ]
  2. The changes in tumor immune microenvironment in patients with neoplastic tumors versus benign lesions [ Time Frame: 3 Weeks ]
  3. The changes in tumor immune microenvironment in patients with stage I-II, versus stage 0 tumors [ Time Frame: 3 Weeks ]
  4. The changes in tumor immune microenvironment in patients with hormone receptor and Her2 positive versus triple negative tumors [ Time Frame: 3 Weeks ]
  5. Serum Serum Thymic Stromal Lymphopoietin (TSLP) levels (picogram/milliliter) before and after topical calcipotriene treatment compared to Vaseline control group [ Time Frame: 3 Weeks ]
  6. Disease free survival [ Time Frame: From the start of treatment up to 15 years ]
    The duration of time measured from the start of treatment until the time of disease progression or death, whichever occurs first.

  7. Number of Participants with Treatment Related Adverse Events [ Time Frame: From the start of treatment until 30 days after the end of treatment, up to 2 months ]
    Adverse events will be assessed using Common Terminology Criteria for Adverse Events (CTCAE v4).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have histologically confirmed benign, premalignant or early malignant breast lesions on core biopsy that will proceed directly to surgical removal without any intervening neoadjuvant chemotherapy.
  • Patients diagnosed with benign breast lesions (papilloma and sclerosing lesion), flat epithelial atypia, atypical ductal hyperplasia, lobular carcinoma in situ (Tis N0 M0; stage 0), ductal carcinoma in situ (Tis N0 M0; stage 0), primary invasive ductal and lobular carcinoma (T1or2 N0or1 M0; stage I-II), who will directly receive surgery and no neoadjuvant chemotherapy.
  • Patients with hormone receptor positive, Her2 positive and triple negative cancers will be eligible.
  • Patients with multicentric and multifocal tumors will be eligible.
  • Age 45 years. To avoid the impact of menstrual cycles-associated alterations in the immune environment of the breast, the age is limited to post-menopausal women.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants scheduled to undergo neoadjuvant therapy for breast cancer.
  • Participants with metastatic breast cancer.
  • Participants with history of breast cancer in the past 5 years.
  • Participants with immunosuppression (e.g., organ transplant recipients and patients with autoimmune diseases requiring immunosuppressive medications including >5mg daily prednisone, methotrexate, cyclosporine, azothioprine, tacrolimus and TNFα blocking agents)
  • Participants with the history of hypercalcemia or clinical evidence of vitamin D toxicity.
  • Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Participants who are receiving any other investigational agents.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to topical calcipotriene ointment.
  • Pregnant women are excluded from this study because topical calcipotriol ointment is a category C agent and its impact on developing fetus is unknown. In addition, premenopausal women are excluded from this study due to the impact of menstrual cycles on immune environment of the breast.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03596073


Contacts
Layout table for location contacts
Contact: Shadmehr Demehri, MD 617-643-6436 sdemehri1@mgh.harvard.edu

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02215
Contact: Shadmehr Demehri, MD    617-643-6436    sdemehri1@mgh.harvard.edu   
Principal Investigator: Shadmehr Demehri, MD         
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Layout table for investigator information
Principal Investigator: Shadmehr Demehri, MD Massachusetts General Hospital

Layout table for additonal information
Responsible Party: Shadmehr Demehri, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT03596073     History of Changes
Other Study ID Numbers: 18-040
First Posted: July 23, 2018    Key Record Dates
Last Update Posted: November 14, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Shadmehr Demehri, Massachusetts General Hospital:
Breast Cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Calcipotriene
Petrolatum
Calcitriol
Dermatologic Agents
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Vitamins
Micronutrients
Nutrients
Growth Substances
Bone Density Conservation Agents
Emollients